Menu

Image of the Day: Tumor Organoids

Miniature versions of bladder cancers could help physicians identify personalized treatment options for patients.

Apr 11, 2018
The Scientist Staff, The Scientist Staff

Organoids created from the bladder cancers of patients mimic the characteristics of each person’s tumor and may be used for screening interventions.COLUMBIA UNIVERSITY IRVING MEDICAL CENTER

Organoids—miniature versions of organs grown in vitro from tissue-specific progenitor cells—were first produced in 2013. Last week (April 5), researchers reported in Cell that they created organoids from human bladder cancer tumors for the first time. The organoids are unique to each patient’s tumor and could offer a novel approach to studying the molecular mechanisms associated with resistance to cancer-fighting drugs.

“The great advantage of organoids is that they are essentially avatars of a patient's tumor,” study coauthor Michael Shen, a geneticist at Columbia University, says in a press release. “Having these personalized laboratory models, which we can make in a matter of weeks, will let us test multiple different drugs on the tumor and help us bring precision medicine to individuals with bladder cancer.”

See “My Mighty Mouse

S.H. Lee et al., “Tumor evolution and drug response in patient-derived organoid models of bladder cancer,” Cell, doi:10.1016/j.cell.2018.03.017, 2018.

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.